Publications
4 shownClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with advanced stage disease respond initially but then...
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
The BCR-ABL tyrosine kinase inhibitor STI571 is well tolerated and has substantial activity in the blast crises of CML and in Ph-positive ALL.
Opportunities and challenges in the development of kinase inhibitor therapy for cancer
The success of the tyrosine kinase imatinib inhibitor (Gleevec, STI571) in treating chronic myeloid leukemia as well as other selected cancers has greatly increased optimism for...
Frequent Co-Authors
Researcher Info
- h-index
- 4
- Publications
- 4
- Citations
- 6,307
- Institution
- University of California, Los Angeles
External Links
Identifiers
- ORCID
- 0000-0003-4955-6475
Impact Metrics
h-index
4
h-index: Number of publications with at least h citations each.